Newsfeeds - Spark Newswire

1 minute read

News

In8bio Sponsored Trial: Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous Î³Î’ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Poste…

By Charles Gross

Today, 9:26 AM

https://clinicaltrials.gov/ct2/show/NCT05664243

INAB

2 minute read

$5 Million Bet On SoFi Technologies? Check Out These 5 Penny Stocks Insiders Are Buying

By Lisa Levin

Today, 9:26 AM

The Dow Jones closed higher by over 100 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

AIKI

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s Intraday Session

By Benzinga Insights

Today, 9:26 AM

Gainers Vapotherm (NYSE:VAPO) shares rose 44.2% to $1.28 during Thursday’s regular session. As of 12:30 EST, this security…

AIMD

1 minute read

B. Riley Securities Downgrades IN8bio to Neutral, Lowers Price Target to $3

By Benzinga Newsdesk

Today, 9:26 AM

B. Riley Securities analyst Kalpit Patel downgrades IN8bio (NASDAQ:INAB) from Buy to Neutral and lowers the price target from $9 to $3.

INAB

1 minute read

IN8bio, Inc. – Common Stock Q3 EPS $(0.34) Down From $(0.25) YoY

By Benzinga Newsdesk

Today, 9:26 AM

IN8bio, Inc. - Common Stock (NASDAQ:INAB) reported quarterly losses of $(0.34) per share. This is a 36 percent decrease over losses of $(0.25) per share from the same period last year.

INAB